MX9306879A - Derivados de piperazina y composiciones farmaceuticas que los contienen,para el tratamiento de enfermedades del conocimiento. - Google Patents

Derivados de piperazina y composiciones farmaceuticas que los contienen,para el tratamiento de enfermedades del conocimiento.

Info

Publication number
MX9306879A
MX9306879A MX9306879A MX9306879A MX9306879A MX 9306879 A MX9306879 A MX 9306879A MX 9306879 A MX9306879 A MX 9306879A MX 9306879 A MX9306879 A MX 9306879A MX 9306879 A MX9306879 A MX 9306879A
Authority
MX
Mexico
Prior art keywords
derivatives
treatment
piperazine
diseases
knowledge
Prior art date
Application number
MX9306879A
Other languages
English (en)
Inventor
Ian Anthony Cliffe
Allan Fletcher
Alan Chapman White
Original Assignee
Wyeth John & Brother Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth John & Brother Ltd filed Critical Wyeth John & Brother Ltd
Publication of MX9306879A publication Critical patent/MX9306879A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención provee, en un aspecto, un método para el tratamientode enfermedades del conocimiento, el cual comprende administrar a un serhumano en necesidad del mismo, una cantidad efectiva de un compuesto defórmula (I) como se define anteriormente o una sal de adición de ácidoaceptable farmacéuticamente del mismo. En un segundo aspecto, la invenciónprovee el uso de un compuesto de fórmula (I), como se define anteriormenteo una sal de adición de ácido aceptable farmacéuticamente del mismo, parala fabricación de un medicamento para el tratamiento de enfermedades delconocimiento.
MX9306879A 1992-11-05 1993-11-04 Derivados de piperazina y composiciones farmaceuticas que los contienen,para el tratamiento de enfermedades del conocimiento. MX9306879A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929223153A GB9223153D0 (en) 1992-11-05 1992-11-05 Piperazine derivatives

Publications (1)

Publication Number Publication Date
MX9306879A true MX9306879A (es) 1995-01-31

Family

ID=10724559

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9306879A MX9306879A (es) 1992-11-05 1993-11-04 Derivados de piperazina y composiciones farmaceuticas que los contienen,para el tratamiento de enfermedades del conocimiento.

Country Status (18)

Country Link
US (1) US5827847A (es)
EP (1) EP0877612B1 (es)
JP (1) JP3238153B2 (es)
AT (1) ATE195422T1 (es)
AU (1) AU682155B2 (es)
CA (1) CA2148593C (es)
DE (1) DE69329252T2 (es)
DK (1) DK0877612T3 (es)
ES (1) ES2149216T3 (es)
GB (1) GB9223153D0 (es)
GR (1) GR3034400T3 (es)
HU (1) HUT72049A (es)
LV (1) LV12734B (es)
MX (1) MX9306879A (es)
PT (1) PT877612E (es)
TW (1) TW252043B (es)
WO (1) WO1994009780A1 (es)
ZA (1) ZA937827B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0710481A1 (en) * 1994-11-02 1996-05-08 Duphar International Research B.V Use of flesinoxan for cognition enhancement
US6271234B1 (en) * 1997-08-01 2001-08-07 Recordati S.A., Chemical And Pharmaceutical Company 1,4-disubstituted piperazines

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2355502A1 (fr) * 1976-06-23 1978-01-20 Roussel Uclaf Application a titre de medicaments d'un derive de la piperazine et de ses sels
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
GB2222768B (en) * 1988-06-17 1992-01-22 Nat Res Dev Analgesic compounds and compositions
GB8909209D0 (en) * 1989-04-22 1989-06-07 Wyeth John & Brother Ltd Piperazine derivatives
US4902687A (en) * 1989-03-27 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
NZ233398A (en) * 1989-04-22 1991-12-23 American Home Prod Aryl- or heteroaryl-substituted piperazine derivatives and pharmaceutical compositions
ATE179973T1 (de) * 1989-04-22 1999-05-15 Wyeth John & Brother Ltd Piperazin-derivate
EP0398413A1 (en) * 1989-05-16 1990-11-22 Duphar International Research B.V "3,4-dehydropiperidine derivatives having psychotropic activity
DK0510068T3 (da) * 1990-01-11 1999-10-25 Upjohn Co Nye 6,7,8,9-tetrahydro-3H-benz(e)indol-heterocycler med virkning på centralnervesystemet
GB9022820D0 (en) * 1990-10-19 1990-12-05 Wyeth John & Brother Ltd Piperazine derivatives
DE4039631A1 (de) * 1990-12-12 1992-06-17 Troponwerke Gmbh & Co Kg Neuroprotektive kombination
IL101722A (en) * 1991-05-02 1996-05-14 Wyeth John & Brother Ltd History of piperazine, their preparation and pharmaceutical preparations containing them
DE4135551A1 (de) * 1991-08-31 1993-03-04 Schering Ag Verwendung von antagonisten oder partiellen agonisten am 5-ht1a-rezeptor zur behandlung und praevention von kognitiven stoerungen

Also Published As

Publication number Publication date
CA2148593A1 (en) 1994-05-11
JPH08502743A (ja) 1996-03-26
DE69329252D1 (de) 2000-09-21
GB9223153D0 (en) 1992-12-16
EP0877612A1 (en) 1998-11-18
ATE195422T1 (de) 2000-09-15
HUT72049A (en) 1996-03-28
DE69329252T2 (de) 2001-03-29
GR3034400T3 (en) 2000-12-29
AU5342194A (en) 1994-05-24
AU682155B2 (en) 1997-09-25
WO1994009780A1 (en) 1994-05-11
HU9501290D0 (en) 1995-06-28
US5827847A (en) 1998-10-27
ZA937827B (en) 1995-04-21
JP3238153B2 (ja) 2001-12-10
TW252043B (es) 1995-07-21
LV12734B (en) 2002-01-20
LV12734A (en) 2001-10-20
ES2149216T3 (es) 2000-11-01
DK0877612T3 (da) 2000-10-09
EP0877612B1 (en) 2000-08-16
CA2148593C (en) 2005-12-06
PT877612E (pt) 2000-11-30

Similar Documents

Publication Publication Date Title
ES2116801T3 (es) Empleo de derivados de adamantano para el tratamiento de tinnitus.
NO306344B1 (no) Nye sulfonamider, anvendelse derav og farmasöytiske preparater inneholdende dem
SE9001329L (sv) Adamantanderivat foer att foerhindra och behandla cerebral ischemi
ES2141174T3 (es) 4-arilmetiloximetil piperidinas como antagonistas de taquiquinina.
ES2087625T3 (es) Derivados de ciclohexano sustituidos, procedimiento para su preparacion y el empleo de los compuestos para el tratamiento de enfermedades.
ES2098023T3 (es) Compuestos de estructura guanidinica y composiciones farmaceuticas que los contienen.
DE69424009T2 (de) Verwendung von (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidinacetamid zur Herstellung eines Medikaments zur Behandlung von Angst
MX9400253A (es) Derivados de piperazina, proceso para su preparacion y composiciones farmaceuticas que los contienen.
ES2103440T3 (es) Nuevas amidas y sulfonamidas naftalenicas, procedimiento de preparacion y composiciones farmaceuticas que las contienen.
DE69328193D1 (de) Verwendung von prodelphidinen zur behandlung von arthrose
MX9306879A (es) Derivados de piperazina y composiciones farmaceuticas que los contienen,para el tratamiento de enfermedades del conocimiento.
DK0646110T3 (da) N-substituerede 3-azabicyclo(3.2.0) heptanderivater som neuroleptika
DE69525633T2 (de) Chinoxalinderivate und ihre therapeutische verwendbarkeit
ATE223379T1 (de) N-aryloxyethylaminderivate zur behandlung der depression
DK0678088T3 (da) N-acylpyrrolidiner og lægemidler til behandling og forebyggelse af cholecystokinin- og gastrinrelaterede sygdomme
DE59409813D1 (de) Imidazolochinoxalinone zur behandlung zentralnervöser erkrankungen
ATE168697T1 (de) Pyrrolidinderivate zur behandlung von cck und gastrin-abhängigen erkrankungen
DE59309469D1 (de) Triazolochinazoline zur behandlung zentralnervöser erkrankungen

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees